US Patent

US10265311 — Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation

Method of Use · Assigned to Puretech Health LLC · Expires 2030-07-21 · 4y remaining

Vulnerability score 81/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods and compositions for treating disorders that are improved by activating muscarinic receptors, using combinations of activators and inhibitors.

USPTO Abstract

Methods for the treatment of CNS disorders using combinations of muscarinic activators and inhibitors, and medicaments comprising muscarinic activators and inhibitors.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3513`	—
`U-3513`	—
`U-3513`	—

Patent Metadata

Patent number: US10265311
Jurisdiction: US
Classification: Method of Use
Expires: 2030-07-21
Drug substance claim: No
Drug product claim: No
Assignee: Puretech Health LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.